(Reuters) - Regeneron Pharmaceuticals Inc said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus.
The company said the trial was ended early because its therapy, REGN-EB3, elicited a "highly statistically significant result" compared to Mapp's ZMapp, which was considered a standard-of-care treatment.
An independent data safety monitoring board ended the trial after reviewing interim mortality data from 499 patients, Regeneron said.
(Reporting by Tamara Mathias in Bengaluru; Editing by Shinjini Ganguli)
